TIRmed Pharma, a biotech company developing innovative treatments for autoimmune
skin diseases, has raised EUR 4.3 million in a funding round led by Sciety and Sciety
Venture Partners. The investment will support the company’s transition into clinical
development of its immunomodulatory treatment for atopic dermatitis – a condition
with significant unmet medical need, where more effective therapies with favorable
safety profiles are still lacking.
The EUR 4.3 million raised will enable the completion of toxicology studies, GMP production,
and initiation of the company’s first Phase Ib clinical trial in patients with atopic dermatitis.
Atopic dermatitis is one of the most common skin diseases worldwide, affecting millions of
people each year. It is a chronic inflammatory condition often associated with intense itching,
skin irritation, and sleep disruption – with a significant negative impact on quality of life.
Despite multiple treatment options available today, the majority of patients experience
insufficient relief, and many existing treatments are limited by short-term efficacy or side
effects. The need for new, more sustainable therapies is substantial.
TIRmed Pharma is developing a novel treatment based on an oligonucleotide applied directly
to the skin, acting locally by modulating the immune system at the site of disease. This
targeted, immunomodulatory mechanism of action helps reduce systemic exposure and
thereby minimizes the risk of side effects – a key advantage over many current treatments.
In preclinical studies, the treatment has shown promising results, including sustained
symptom relief for up to 15 months after just five applications over two weeks. The goal is to
offer a more effective, long-lasting, and safer alternative for patients with atopic dermatitis –
improving both treatment outcomes and overall quality of life.
“This capital injection enables us to take the decisive step into clinical development and
move closer to a future where patients have access to more durable and effective treatment.
The strong support from Sciety and their investor network gives us both the momentum and
the means to accelerate our development,” says Leo Holmgren, CEO of TIRmed Pharma.
The funding round attracted strong investor interest, underscoring both the growing need for
innovation in dermatology and confidence in TIRmed Pharma’s strategy.
“TIRmed Pharma takes a clear approach to addressing a significant medical need in
dermatology. We see a feasible clinical strategy, strong preclinical data, and an experienced
team ready to take the next step. That makes the company a natural fit for our portfolio,”
says Andreas Lindblom, Managing Partner at Sciety.
The global market for atopic dermatitis treatments is currently valued at approximately USD
9.3 billion and is projected to grow by 8–10 percent annually through 2032.
For more information, please contact:
Leo Holmgren, CEO
Phone: +46 70 049 18 42
Email: leo.holmgren@tirmedpharma.com
About TIRmed Pharma
TIRmed Pharma is a biotechnology company developing next-generation immunomodulatory
therapies for autoimmune skin diseases, with an initial focus on Atopic Dermatitis (eczema).
Despite being a common condition, current treatments often provide only symptomatic relief.
The company’s drug candidate, TIR-C, is a topical oligonucleotide-based treatment that
regulates immune responses and targets the disease’s underlying mechanisms rather than
just controlling symptoms. Promising preclinical results support its potential to provide long-
lasting relief and reduce treatment burden. Building on expertise in immunology and drug
development, the company is pioneering new solutions in dermatological immunotherapy to
enable more targeted and effective treatment options.
TIRmed Pharma is headquartered in Stockholm, Sweden. For more information, visit
tirmedpharma.com and follow TIRmed on LinkedIn.
About Sciety
Sciety is a leading investment company, committed to supporting the growth of
innovative life science and health tech companies in the Nordic region. We invest
alongside Sciety Venture Partners, comprising family offices and private investors, as
well as venture capital firms. Our mission is to enable the full potential of life science
innovations, helping to bring breakthroughs in healthcare to people all over the world.
Learn more at sciety.com/sv and follow Sciety on LinkedIn.